Synapse - Claudia Diamonte

Results (34)

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab

Journal Article

Adusumilli, P. S.; Zauderer, M. G.; Rivière, I.; Solomon, S. B.; Rusch, V. W.; O'Cearbhaill, R. E.; Zhu, A.; Cheema, W.; Chintala, N. K.; Halton, E.; more...
Cancer Discovery (2021)

Fulltext@MSK | Save

Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia

Research Letter

Perica, K.; Flynn, J.; Curran, K. J.; Rivere, I.; Wang, X.; Senechal, B.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; more...
Leukemia (2021)

Fulltext@MSK | Save

Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells

Journal Article

Pennisi, M.; Sanchez-Escamilla, M.; Flynn, J. R.; Shouval, R.; Alarcon Tomas, A.; Silverberg, M. L.; Batlevi, C.; Brentjens, R. J.; Dahi, P. B.; Devlin, S. M.; more...
Blood Advances (2021)

Fulltext@MSK | Save

Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy

Journal Article

Wudhikarn, K.; Flynn, J. R.; Rivière, I.; Gönen, M.; Wang, X.; Senechal, B.; Curran, K. J.; Roshal, M.; Maslak, P. G.; Geyer, M. B.; more...
Blood (2021)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
Blood (2020)

Fulltext@MSK | Save

International prognostic index predicts outcomes in patients with relapsed and refractory large diffuse B cell lymphoma treated with commercial CAR T cells

Meeting Abstract

Garcia-Recio, M.; Wudhikarn, K.; Pennisi, M.; Alonso-Trillo, R.; Flynn, J.; Roni, S.; Batlevi, Y.; Silverberg, M. L.; Batlevi, C. W.; Brentjens, R.; more...
Bone Marrow Transplantation (2020)

Fulltext@MSK | Save

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

Guidelines

Maus, M. V.; Alexander, S.; Bishop, M. R.; Brudno, J. N.; Callahan, C.; Davila, M. L.; Diamonte, C.; Dietrich, J.; Fitzgerald, J. C.; Frigault, M. J.; more...
Journal for ImmunoTherapy of Cancer (2020)

Fulltext@MSK | Save

A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)